HURA TuHURA Biosciences, Inc./NV
FY2024 10-K
TuHURA Biosciences, Inc./NV (HURA) filed its fiscal year 2024 10-K annual report with the SEC on Mar 31, 2025. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2024 10-K
Business Overview
- • Core business: Clinical-stage immuno-oncology focused on innate immune agonists and tumor microenvironment modulators to overcome resistance to checkpoint inhibitors
- • New emphasis: Acquisition of Kineta, Inc. to incorporate anti-VISTA antibody checkpoint inhibitor targeting acquired resistance
Management Discussion & Analysis
- • Revenue and profitability details not disclosed in provided text
- • No segment performance data available
Risk Factors
- • FDA partial clinical hold on Phase 3 IFx-2.0 trial to be lifted by Q2 2025 per agreement, critical to initiation of pivotal registration study
- • Direct exposure to regulatory milestones in Kintara Merger earnout: enrollment of 10 metastatic breast cancer patients plus 8 weeks follow-up by Dec 31, 2025
Financial SummaryXBRL
Revenue
$0
Net Income
-$22M
ROE
-148.6%
Total Assets
$20M
EPS (Diluted)
$-1.21
Operating Cash Flow
-$15M
Source: XBRL data from TuHURA Biosciences, Inc./NV FY2024 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on TuHURA Biosciences, Inc./NV
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.